Search results
Results from the WOW.Com Content Network
Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch. [177] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy ...
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India. [83] [84] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy groups ...
At Novartis, patent expiration for blockbuster drugs Diovan and Zometa shaved more than $2 billion from the top line in 2013. Sales of blood pressure drug Diovan sank 20% and revenue from Zometa ...
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 ...
In 2017, the ABX patent was also acquired by Endocyte [16] and Endocyte together with the above two sets of patents was acquired by Novartis in 2018. [17] Efficacy and safety was initially investigated as a compassionate access treatment in Germany with high tumor targeting and low doses to normal organs. [18]
Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported fourth-quarter adjusted earnings per share of $1.98, beating the street view of ...
A settlement was reached where Roche Holding A.G. agreed to buy the global semi-exclusive nucleic acid test (NAT) patents for HCV and HIV from Chiron. [25] Bayer, the company which bought Chiron Diagnostics, sued Chiron Corporation in 2002 citing that it hid patent and equipment problems from them during purchase negotiations. [32]